Patents by Inventor Gregory Alan Lazar

Gregory Alan Lazar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fc variants with altered binding to FcRn
    Patent number: 11932685
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: March 19, 2024
    Assignee: XENCOR, INC.
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • OPTIMIZED ANTIBODIES THAT TARGET CD19
    Publication number: 20230340144
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: February 21, 2023
    Publication date: October 26, 2023
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • FLT3 LIGAND FUSION PROTEINS AND METHODS OF USE
    Publication number: 20230279067
    Abstract: The invention provides an effectorless immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.
    Type: Application
    Filed: November 21, 2022
    Publication date: September 7, 2023
    Applicant: Genentech, Inc.
    Inventors: Yichin LIU, Christine Carine MOUSSION, Travis William BAINBRIDGE, lraj HOSSEINI, Gregory Alan LAZAR, Sivan COHEN, Christopher Charles KEMBALL, Jill M. SCHARTNER
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
    Publication number: 20230227560
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: August 11, 2022
    Publication date: July 20, 2023
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Optimized antibodies that target CD19
    Patent number: 11618788
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: April 4, 2023
    Assignee: XENCOR, INC.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
    Publication number: 20230056900
    Abstract: The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
    Type: Application
    Filed: May 23, 2022
    Publication date: February 23, 2023
    Inventor: Gregory Alan Lazar
  • FLT3 ligand fusion proteins and methods of use
    Patent number: 11542308
    Abstract: The invention provides an effectorless immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: January 3, 2023
    Assignee: Genentech, Inc.
    Inventors: Yichin Liu, Christine Carine Moussion, Travis William Bainbridge, Iraj Hosseini, Gregory Alan Lazar, Sivan Cohen, Christopher Charles Kemball, Jill M. Schartner
  • Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
    Publication number: 20220324946
    Abstract: The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
    Type: Application
    Filed: March 25, 2022
    Publication date: October 13, 2022
    Inventor: Gregory Alan LAZAR
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 11447552
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: September 20, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • FLT3 LIGAND FUSION PROTEINS AND METHODS OF USE
    Publication number: 20220289803
    Abstract: The invention provides an effectoriess immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 15, 2022
    Applicant: Genentech, Inc.
    Inventors: Yichin LIU, Christine Carine MOUSSION, Travis William BAINBRIDGE, Iraj HOSSEINI, Gregory Alan LAZAR, Sivan COHEN, Christopher Charles KEMBALL, Jill M. SCHARTNER
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20220281964
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: May 17, 2022
    Publication date: September 8, 2022
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 11434295
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: September 6, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • FUSION PROTEINS
    Publication number: 20220211818
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 7, 2022
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20220112307
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: December 13, 2021
    Publication date: April 14, 2022
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
  • Fusion proteins and methods of use
    Patent number: 11253574
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 22, 2022
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210395363
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 23, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc variants with altered binding to FcRn
    Patent number: 11198739
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: December 14, 2021
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20210277095
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: October 23, 2020
    Publication date: September 9, 2021
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
    Publication number: 20210179693
    Abstract: The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 17, 2021
    Inventor: Gregory Alan Lazar
  • Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
    Publication number: 20210163577
    Abstract: The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
    Type: Application
    Filed: December 21, 2020
    Publication date: June 3, 2021
    Inventor: Gregory Alan Lazar